endoribonuclease

IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity.

IRE1α kinase-IN-1 is a highly selective IRE1α (ERN1) inhibitor, with an IC50 of 77 nM, displaying 100-fold selectivity over the IRE1β isoform. It inhibits ER stress-induced IRE1α oligomerization and autophosphorylation, as well as IRE1α RNase activity (IC50=80 nM).

GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.

HCoV-229E-IN-1 is a potent inhibitor of HCoV-229E replication, demonstrating efficacy with EC50 values of 0.65 μM in MTS cells and 0.6 μM in CPE cells[1].

ZINC000104379474 is a compound targeting SARS-CoV-2 endoribonuclease.

SARS-CoV-2-IN-97 (Compound CO-01) is an inhibitor of the SARS-CoV-2Nsp15 endoribonuclease, exhibiting an IC50 of 53.5 μM. It demonstrates low cytotoxicity in A549-AT cells with an IC50 value of 134 μM.

GP17 is a type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.

C-467929 is an inhibitor of the Nsp15 endoribonuclease, exhibiting an IC50 value of 8 μM. This compound binds to the SARS-CoVNsp15 protein and is applicable for infection research.